Lisa Suennen, known as the ‘Venture Valkyrie’, has taken on a pivotal role as the managing partner of American Heart Association Ventures, managing a portfolio of $200 million aimed at transforming scientific research into viable commercial products. This initiative reflects a growing trend among medical organizations, such as the American Cancer Society and Breakthrough T1D, which are establishing venture arms to foster innovation aligned with their health missions.
The current landscape for venture capital presents significant challenges, particularly with a notable decline in government funding for academic biomedical research. This has made AHA Ventures’ role increasingly critical as it seeks to fill the funding gap exacerbated by recent political shifts affecting NIH grant allocations. With thousands of grants halted due to misalignment with current political agendas, the need for alternative funding sources has never been more urgent, positioning AHA Ventures as a key player in sustaining biomedical innovation.
Get started today with Solo access →
